Sakaguchi Takatoshi, Nagahama Yasuharu, Hamada Nanako, Singh Shailendra Kumar, Mikami Hayato, Maeda Kazuhiko, Akira Shizuo
Laboratory of Host Defense, Immunology Frontier Research Center, Osaka University, Suita 565-0871, Japan.
Host Defense Laboratory, Immunology Unit, Osaka Research Center for Drug Discovery, Otsuka Pharmaceutical Co., Ltd., Minoh 562-0029, Japan.
Nutrients. 2024 Nov 29;16(23):4151. doi: 10.3390/nu16234151.
Metabolic-dysfunction-associated steatotic liver disease (MASLD) is a progressive liver disorder that possesses metabolic dysfunction and shows steatohepatitis. Although the number of patients is globally increasing and many clinical studies have developed medicine for MASLD, most of the studies have failed due to low efficacy. One reason for this failure is the lack of appropriate animal disease models that reflect human MASLD to evaluate the potency of candidate drugs. We developed a novel choline-deficient and 0.11%-methionine-added high-fat diet (CDAHFD)-based (MASH) diet that can induce murine metabolic-dysfunction-associated steatohepatitis (MASH) without severe body weight loss. We performed kinetic analyses post-feeding and proposed an appropriate timing of MASH pathogenesis by quantitatively analyzing steatosis, inflammation, and fibrosis. This MASH diet induced liver fibrosis earlier than the conventional CDAHFD model. In brief, lipid accumulation, inflammation, and fibrosis started after 1 week from feeding. Lipid accumulation increased until 8 weeks and declined thereafter; on the other hand, liver fibrosis showed continuous progression. Additionally, immune cells, especially myeloid cells, specifically accumulated and induced inflammation in the initiation stage of MASH. The novel MASH diet promotes the dynamics of lipid deposition and fibrosis in the liver, similar to human MASH pathophysiology. Furthermore, immune-cell-derived inflammation possibly contributes to the initiation of MASH pathogenesis. We propose this model can be the new pre-clinical MASH model to discover the drugs against human MASH by evaluating the interaction between parenchymal and non-parenchymal cells.
代谢功能障碍相关脂肪性肝病(MASLD)是一种具有代谢功能障碍并表现为脂肪性肝炎的进行性肝脏疾病。尽管全球患者数量在增加,并且许多临床研究已开发出针对MASLD的药物,但大多数研究由于疗效不佳而失败。失败的一个原因是缺乏能够反映人类MASLD以评估候选药物效力的合适动物疾病模型。我们开发了一种基于新型胆碱缺乏和添加0.11%蛋氨酸的高脂饮食(CDAHFD)的(MASH)饮食,它可以诱导小鼠代谢功能障碍相关脂肪性肝炎(MASH),而不会导致严重体重减轻。我们在喂食后进行了动力学分析,并通过定量分析脂肪变性、炎症和纤维化提出了MASH发病机制的合适时间。这种MASH饮食比传统的CDAHFD模型更早诱导肝纤维化。简而言之,喂食1周后开始出现脂质积累、炎症和纤维化。脂质积累在8周前增加,此后下降;另一方面,肝纤维化呈持续进展。此外,免疫细胞,尤其是髓样细胞,在MASH的起始阶段特异性积聚并诱导炎症。这种新型MASH饮食促进了肝脏中脂质沉积和纤维化的动态变化,类似于人类MASH的病理生理学。此外,免疫细胞衍生的炎症可能有助于MASH发病机制的起始。我们提出,通过评估实质细胞和非实质细胞之间的相互作用,该模型可以成为发现针对人类MASH药物的新的临床前MASH模型。